Danaher Corporation DHR shares are trading lower in the premarket session on Wednesday.
The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.
The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.
The company exited the quarter with cash and equivalents worth $2.078 billion, and inventories worth $2.330 billion.
Danaher’s long-term debt as of quarter end totaled $15.50 billion. Operating cash flow was $2.0 billion in the fourth quarter and non-GAAP free cash flow was $1.5 billion.
Rainer M. Blair, President and Chief Executive Officer, stated, “Good execution by our team also drove solid cash flow and operating margin expansion.”
Outlook: Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter.
However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.
Blair continued, “Looking ahead, we believe Danaher is better positioned than at any point in our 40-year history”.
“The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash flow.”
Price Action: DHR shares are trading lower by 5.48% to $234.26 premarket at last check Wednesday.
Read Next:
Photo via Shutterstock.
Overview Rating:
Speculative
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
